Anchored by deep expertise and a high-touch partnership model, Allucent excels in clinical development operations, providing a breadth of specialized services and therapeutic experience geared toward small and mid-size biopharma companies.
Allucent’s flexible clinical development services enable our partners to successfully navigate the complexities of managing and conducting early and late-stage multi-national programs through dedicated study start-up and patient engagement teams, tailored onsite, hybrid or decentralized clinical trials (DCT), pharmacovigilance, data management and biostatistics, and medical monitoring.
Our global workforce possesses deep clinical and technical experience coupled with a passion for innovative breakthrough science and assisting clients in delivering novel treatments to patients.
Therapeutic Expertise
Allucent provides robust scientific and clinical development solutions for complex therapeutic areas, modalities, and devices, with a focus on oncology, neuroscience, immunology and inflammation, infectious disease and vaccines, cell and gene therapy, and rare diseases.
Clinical Strategy
Our clinical strategy services span design and execution of full product development programs, from exploratory IND and first-in-human to IND (or equivalent), clinical development, marketing approval, through to Phase IV post-marketing research.
Study Start-Up & Site Intelligence
As a clinical development consulting partner, Allucent provides strategic guidance and comprehensive support across the full spectrum of product development programs from exploratory IND and first-in-human studies through IND submissions (or equivalent), clinical development phases, marketing approval, and Phase IV post-marketing research.
Patient Recruitment & Retention
Our dedicated Patient Engagement team offers tailored strategies to support patient recruitment, engagement, diversity, and compliance, working across a range of therapeutic areas and clinical study types, including on-site, decentralized, and hybrid trials as part of our comprehensive clinical development service.
Study Experience
1015+
clinical trials conducted
Trials in
75+
countries worldwide
825+
regulatory submissions per year
50+
approved and marketed Products
Explore
Additional Resources
Blogs
The High Cost of Standing Still: What Sponsors Risk by Ignoring ICH E6 (R3)
Learn More
Blogs
Navigating Regulatory Uncertainty: Adapting to FDA Changes in 2025
Learn More
Blogs
Insights from the Accelerating Clinical Trials in the EU (ACT EU) Workshop on ICH E6(R3): A Step Towards a Fit-for-Purpose Future
Learn More